Semaglutide

Semaglutide is a GLP-1 receptor agonist sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. It mimics the hormone GLP-1, which is released after eating, to slow gastric emptying, increase satiety, and improve glucose-dependent insulin secretion.

Average weight loss on semaglutide in clinical trials runs about 15–17% of body weight at the highest doses. Nausea, vomiting, and other GI side effects are the most common reasons for discontinuation, and the rate of side effects varies substantially between individuals.

The GLP1R gene encodes the GLP-1 receptor, the direct target of semaglutide. A common signal-peptide variant (rs10305420, Pro7Leu) alters how efficiently the receptor is processed and trafficked to the cell surface, changing the strength of the downstream signal when GLP-1 or semaglutide binds.

The Leu7 allele is found in roughly 30–40% of European-ancestry populations. Carriers tend to have a stronger response to semaglutide, both in terms of weight loss and in terms of GI side effects.

In a 2025 analysis, individuals carrying one or two copies of the GLP1R Leu7 allele showed dose-dependent additional weight loss compared with Pro7/Pro7 individuals, roughly 0.76 kg of additional loss per copy at standard maintenance doses, alongside a parallel increase in nausea and vomiting risk.

This is not a contraindication signal. Most patients on semaglutide do well, and the variant does not change whether semaglutide is the right drug for a given patient, but it does help set expectations and may inform titration speed.

Typical Response (Pro7/Pro7)

• Effect: Average weight loss and average GI side-effect risk.
• Clinical consequence: Standard dosing and titration are expected to produce a typical response.
• Recommendation: Use the standard 0.25 → 0.5 → 1.0 → 2.0 → 2.4 mg titration schedule (Wegovy) or the diabetes-equivalent.

Enhanced Response — Heterozygous (Pro7/Leu7)

• Effect: Modestly greater weight loss; modestly higher nausea/vomiting risk.
• Clinical consequence: A single titration step that goes well in average patients may produce more nausea than expected.
• Recommendation: Standard dosing, with a low threshold for slowing the titration if early GI side effects emerge.

Enhanced Response — Homozygous (Leu7/Leu7)

• Effect: Greater weight loss and meaningfully higher nausea/vomiting risk.
• Clinical consequence: GI side effects more likely to be dose-limiting during titration.
• Recommendation: Consider a slower titration schedule from the start; counsel that GI side effects are more likely but tend to subside with continued use at a steady dose.

Indeterminate / Not Available

• Effect: Unknown impact.
• Recommendation: Standard dosing and titration; monitor response.

If semaglutide is poorly tolerated despite a slowed titration, alternatives include tirzepatide (Mounjaro / Zepbound), which adds GIP-receptor activity and may produce greater weight loss but is sensitive to a different genetic variant (GIPR rs1800437) for GI side effects.

• Nature, 2025 — GLP1R signal-peptide variants and incretin response
• FDA — Semaglutide prescribing information

Learn more about how genetics may affect your response to Semaglutide and related medications:

• Retatrutide Pharmacogenetics: Triple Agonist Genetics (Investigational)
• Why Isn't Ozempic or Wegovy Working for Me? The GLP1R Connection
• Tirzepatide (Mounjaro, Zepbound) Not Working: GLP1R and GIPR Genetics